Back to Treatments

Treatment

Tisagenlecleucel (CAR T-cell Therapy)

1
Conditions
6
Trials
2,000
Participants
25%
Average Safety

Condition Evidence

Acute lymphoid leukemia

6 trials · 2,000 participants

92% effectiveness · 25% safety
Tisagenlecleucel (CAR T-cell Therapy) | DFDA